ENTA - NASDAQ

Enanta Pharmaceuticals, Inc.

ENTA·NASDAQ

$11.90

-1.1%

HealthcareBiotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$276.31M

EPS-3.8400

P/E Ratio-3.10

Earnings Date08/10/2026

280.73M

Assets

-25%

3Y-26.0%

5Y-42.0%

10Y-

216.01M

Total Liabilities

-13%

3Y+265.0%

5Y+607.0%

10Y+1805.0%

64.72M

Total Equity

-50%

3Y-80.0%

5Y-86.0%

10Y-76.0%

Enanta Pharmaceuticals, Inc. Funding & Solvency Profile

ENTA · NASDAQ

Current Assets

Cash & Cash Equivalents32.30M

Net Receivables6.88M

Inventory0.00

Other Current Assets8.59M

Total Current Assets204 M

Non-Current Assets

Property, Plant & Equipment72.94M

Goodwill & Intangible Assets0.00

Long-Term Investments3.36M

Other Non-Current Assets92.00K

Total Non-Current Assets76 M

Total Assets

280.73M

Financial Health Analysis

Current Ratio

4.21x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.34x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

156 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

73% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Enanta Pharmaceuticals, Inc. Balance Sheet

ENTA • NASDAQ

Enanta Pharmaceuticals, Inc. Balance Sheet	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	32.3M	37.2M	85.4M	44M	57.2M	87.1M	51.2M	63.9M	65.7M	16.6M	21.7M	30.7M	8.9M	10.5M	6.8M
Short-Term Investments	156.6M	211M	284.5M	205.2M	186.8M	299.5M	284M	244.8M	158M	193.5M	123.5M	60.1M	92.6M	33.3M	16.5M
Cash & Short-Term Investments	188.9M	248.2M	369.9M	249.2M	244M	386.6M	335.2M	308.7M	223.7M	210.1M	145.2M	90.8M	101.5M	43.8M	23.3M
Net Receivables	6.9M	38.6M	39.6M	49M	60.8M	23.5M	51.3M	67.2M	10.6M	12.8M	15.7M	4.5M	1.6M	2.9M	261K
Accounts Receivables	6.9M	6.6M	8.6M	20.3M	23.6M	23.5M	51.3M	67.2M	10.6M	12.8M	15.3M	1.7M	808K	1M	261K
Other Receivables	0.0	32M	31M	28.7M	37.3M	0.0	0.0	0.0	0.0	0.0	433K	2.8M	784K	1.9M	0.0
Prepaids	0.0	12.4M	13.3M	0.0	14.2M	13.7M	15.3M	4.5M	3.5M	9.2M	8.3M	1.6M	1.6M	604K	369K
Other Current Assets	8.6M	608K	0.0	13.4M	0.0	13M	0.0	4.5M	3.5M	9.2M	9.7M	12.7M	1.6M	0.0	1.1M
Total Current Assets	204.3M	299.9M	422.8M	311.7M	319M	436.8M	401.8M	380.4M	237.8M	232.2M	170.6M	108M	104.7M	47.3M	25.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	72.9M	73.3M	34.7M	29.7M	10.7M	15.6M	10.9M	8.4M	8M	8M	5.9M	1.8M	1.1M	611K	534K
Long-Term Investments	3.4M	3.4M	4M	33.3M	109M	32.6M	65M	16.4M	70M	32.1M	64.2M	41M	10.7M	1.7M	0.0
Tax Assets	0.0	0.0	0.0	5.2M	2.1M	345K	11.3M	8.4M	10.1M	8.4M	4.6M	4.2M	0.0	0.0	0.0
Other Non-Current Assets	92K	94K	803K	696K	92K	700K	700K	700K	608K	608K	608K	436K	436K	2.6M	463K
Total Non-Current Assets	76.4M	76.8M	39.5M	68.9M	121.8M	49.3M	88M	33.8M	88.8M	49.1M	75.4M	47.4M	12.3M	4.9M	997K
Total Assets	280.7M	376.7M	462.3M	380.6M	440.9M	486.1M	489.8M	414.2M	326.6M	281.3M	246M	155.4M	117M	52.2M	26.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.9M	8M	4.1M	6M	9.5M	5.7M	6.7M	6.1M	3.7M	3.4M	1.5M	1.9M	1.5M	1.9M	566K
Accounts Payable	1.9M	8M	4.1M	6M	9.5M	5.7M	6.7M	4.7M	3.7M	3.4M	1.5M	1.9M	1.5M	1.9M	566K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	12.8M	13.5M	18.3M	6.4M	6.1M	14.2M	15.9M	9.9M	8M	4.4M	2.6M	2.9M	3M	3.9M	1.6M
Short Term Debt	30.7M	34.5M	35.1M	2.9M	4.2M	4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	3.1M	1.5M	5.3M	2.9M	4.2M	4.3M	0.0	0.0	79K	73K	69K	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M	9.3M	0.0	1.2M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.3M	0.0	1.2M	0.0	10K	17K	0.0
Other Current Liabilities	0.0	0.0	0.0	11.6M	12.1M	-4.3M	0.0	0.0	9.2M	0.0	2.5M	0.0	0.0	0.0	0.0
Total Current Liabilities	48.6M	57.5M	62.8M	29.8M	36.2M	24.2M	22.6M	16M	21M	7.9M	6.7M	4.7M	4.5M	5.7M	2.1M
NON-CURRENT LIABILITIES
Long Term Debt	112.4M	136.1M	160.9M	1.4M	1.5M	1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-318K	-457K	15K	207K	462K	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	7.6M	5.2M	2.1M	0.0	1.7M	1.8M	1.2M	745K	448K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	260K	231K	663K	454K	558K	1.1M	4.5M	4.2M	3.6M	3M	2.6M	2M	2M	2.5M	155.9M
Total Non-Current Liabilities	167.5M	190.3M	182.8M	29.4M	5.3M	6.4M	4.7M	4.5M	4M	3.5M	3.2M	2M	2M	2.5M	155.9M
Capital Lease Obligations	57.9M	55.5M	26.5M	25.3M	5.3M	8.1M	200K	293K	458K	531K	598K	0.0	0.0	0.0	0.0
Total Liabilities	216M	247.8M	245.5M	59.3M	41.4M	30.6M	27.3M	20.5M	25M	11.3M	9.9M	6.8M	6.5M	8.2M	158.1M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2K	-2K	-2K	-2K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	1.6M	762K	159K	163K	202K	117M	159.3M	0.0
Common Stock	214K	212K	211K	208K	202K	201K	197K	194K	191K	190K	187K	188K	181K	13K	53K
Additional Paid-In Capital	469.8M	451.3M	424.7M	398M	351M	327M	298.4M	276.5M	256.2M	242.1M	230M	221.6M	217.7M	0.0	0.0
Retained Earnings	-404.9M	-323M	-207M	-73.2M	48.6M	127.6M	163.7M	117.4M	45.4M	27.6M	6M	-73M	-107.5M	-115.4M	-132M
Accumulated Other Comprehensive Income/Loss	-339K	302K	-1.2M	-3.7M	-382K	844K	146K	-398K	-112K	19K	33K	-100K	-2K	10K	-1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-404K	0.0	0.0	153.9M
Total Stockholders' Equity	64.7M	128.8M	216.7M	321.3M	399.4M	455.6M	462.5M	393.7M	301.7M	269.9M	236.2M	148.7M	110.5M	43.9M	-132M
Total Equity	64.7M	128.8M	216.7M	321.3M	399.4M	455.6M	462.5M	393.7M	301.7M	269.9M	236.2M	148.7M	110.5M	43.9M	-132M
SUMMARY
Total Liabilities & Equity	280.7M	376.7M	462.3M	380.6M	440.9M	486.1M	489.8M	414.2M	326.6M	281.3M	246M	155.4M	117M	52.2M	26.1M
Total Investments	159.9M	214.3M	288.5M	238.5M	295.8M	332.2M	349M	261.2M	228M	225.6M	187.7M	101.1M	103.3M	34.9M	16.5M
Total Debt	201.1M	226.1M	222.4M	26.7M	6.8M	9.6M	200K	293K	458K	531K	598K	200K	0.0	0.0	0.0
Net Debt	168.8M	188.8M	137.1M	-17.3M	-50.4M	-79M	-51M	-63.6M	-65.2M	-16M	-21.1M	-30.5M	-8.9M	-10.5M	-6.8M
Shares Outstanding	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357	21,377,357

SEC Filings

ENTA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 11, 2026	2026	View Filing
S-3 S-3 N/A	February 11, 2026	February 11, 2026		View Filing
10-Q 10-Q 2025 Q4 Q4	February 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 09, 2026	February 09, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	January 26, 2026	March 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	November 19, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 17, 2025	November 17, 2025	2025	View Filing

Showing 1 to 10 of 186 filings

Related Guides

Blog Categories

Continue your ENTA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.